Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
- Takeuchi, Tokashiki Picked as Senior Vice Health Minister
October 13, 2015
- TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
- FY2013 Medical Expenditure Tops 40 Trillion Yen to Hit New High
October 9, 2015
- Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
- Abe’s New Cabinet Retains Shiozaki, Pro-Generics Kono Named as Administrative Reform Minister
October 8, 2015
- 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
- MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
- Humanitarian Trial Data Will Be Supplementary Reference to Confirmatory Studies: Govt
October 5, 2015
- Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
October 2, 2015
- PAFSC Committee Approves Resumed Shipments of Kaketsuken’s Venilon due to Potential Shortage of Substitutes
October 2, 2015
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- JPWA Calls for Fair Sharing of Distribution Costs for Premium-Granted Products
October 1, 2015
- Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
- Generic Drug Prices in Japan “Not Necessarily High” Compared to Other Countries: Pres. Yoshida of JGA
October 1, 2015
- 2 Firms Mulling Confidentiality Accords to In-License 1st Drug Seed via AMED
September 30, 2015
- Editor’s Pick: Five Healthcare News Headlines for September 14 - September 27
September 29, 2015
- MHLW Gives Greenlight to AbbVie’s Hep C Drug, Other Products
September 29, 2015
- Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…